Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci120 in healthy adult participants
NCT07040930Phase 1Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GenSci120 in rheumatoid arthritis (RA), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Treatment-Emergent Adverse Events at 169 days, Serious Adverse Events at 169 days and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
GenSci120
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07040930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07040930.